Positions

Selected Publications

Academic Article

Year Title Altmetric
2020 Developing effective combination therapy for pancreatic cancer: An overview.  Pharmacological Research.  155. 2020
2020 The combination of BET and PARP inhibitors is synergistic in models of cholangiocarcinoma.  Cancer Letters.  468:48-58. 2020
2019 The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors.  EBioMedicine.  44:419-430. 2019
2018 FTY720 enhances the anti-tumor activity of carboplatin and tamoxifen in a patient-derived xenograft model of ovarian cancer.  Cancer Letters.  436:75-86. 2018
2018 Targeting PIM kinase as a therapeutic strategy in human hepatoblastoma.  Oncotarget.  9:22665-22679. 2018
2018 Pediatric anaplastic embryonal rhabdomyosarcoma: Targeted therapy guided by genetic analysis and a patient-derived xenograft study.  Frontiers in Oncology.  7. 2018
2018 JQ1 induces DNA damage and apoptosis, and inhibits tumor growth in a patient-derived xenograft model of cholangiocarcinoma.  Molecular Cancer Therapeutics.  17:107-118. 2018
2017 Whole exome sequencing identified sixty-five coding mutations in four neuroblastoma tumors.  Scientific Reports.  7. 2017
2016 The tumor-associated glycosyltransferase ST6Gal-I regulates stem cell transcription factors and confers a cancer stem cell phenotype.  Cancer Research.  76:3978-3988. 2016
2016 The BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft models.  Oncogene.  35:833-845. 2016
2016 Dysregulated human Tyrosyl-DNA phosphodiesterase I acts as cellular toxin.  Oncotarget.  7:86660-86674. 2016
2015 ICAM-2 confers a non-metastatic phenotype in neuroblastoma cells by interaction with α-actinin.  Oncogene.  34:1553-1562. 2015
2015 The role of ICAM-2 in neuroblastoma.  Oncoscience.  2:915-916. 2015
2013 Development and Histopathological Characterization of Tumorgraft Models of Pancreatic Ductal Adenocarcinoma.  PLoS ONE.  8. 2013
2013 N-glycosylation of ICAM-2 is required for ICAM-2-mediated complete suppression of metastatic potential of SK-N-AS neuroblastoma cells.  BMC Cancer.  13. 2013
2009 Cell adhesion molecules as targets for therapy of neuroblastoma..  Cancer Biology and Therapy.  8:306-311. 2009
2008 ICAM-2 expression mediates a membrane-actin link, confers a nonmetastatic phenotype and reflects favorable tumor stage or histology in neuroblastoma.  PLoS ONE.  3. 2008
2007 Tumor-targeted enzyme/prodrug therapy mediates long-term disease-free survival of mice bearing disseminated neuroblastoma.  Cancer Research.  67:22-25. 2007
2006 Development of a tumor-selective approach to treat metastatic cancer.  PLoS ONE.  1. 2006
2006 Development of an etoposide prodrug for dual prodrug-enzyme antitumor therapy..  Molecular Cancer Therapeutics.  5:1577-1584. 2006
2005 Inhibition of acetylcholinesterase by the anticancer prodrug CPT-11..  Chemico-Biological Interactions.  157-158:247-252. 2005
2005 Inhibition of carboxylesterases by benzil (diphenylethane-1,2-dione) and heterocyclic analogues is dependent upon the aromaticity of the ring and the flexibility of the dione moiety..  Journal of Medicinal Chemistry.  48:5543-5550. 2005
2005 The crystal structure of the complex of the anticancer prodrug 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothecin (CPT-11) with Torpedo californica acetylcholinesterase provides a molecular explanation for its cholinergic action..  Molecular Pharmacology.  67:1874-1881. 2005
2005 Development of prodrugs for enzyme-mediated, tumor-selective therapy. 2005
2004 Characterization of inhibitors of specific carboxylesterases: development of carboxylesterase inhibitors for translational application..  Molecular Cancer Therapeutics.  3:903-909. 2004
2003 Activation of a camptothecin prodrug by specific carboxylesterases as predicted by quantitative structure-activity relationship and molecular docking studies..  Molecular Cancer Therapeutics.  2:1171-1181. 2003
2003 Synthesis and evaluation of esters and carbamates to identify critical functional groups for esterase-specific metabolism.  Bioorganic and Medicinal Chemistry.  11:3237-3244. 2003

Education And Training

  • Doctor of Philosophy in Pharmacology, Florida Agricultural & Mechanical University 2001

    • Full Name

  • Karina Yoon